Table: Nippon Shinyaku -Q1 group results (IFRS)
Aug 7 (Reuters)-
Nippon Shinyaku Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2025 Jun 30, 2024 Mar 31, 2026
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 39.55 39.13 166.00
(+1.1 pct) (+5.7 pct) (+3.6 pct)
Operating 10.08 11.08 30.00
(-9.0 pct) (-0.8 pct) (-15.4 pct)
Pretax 10.50 11.41 30.60
(-7.9 pct) (-0.3 pct) (-15.3 pct)
Net 8.26 10.26 24.00
(-19.6 pct) (+17.3 pct) (-26.3 pct)
EPS Basic 122.52 yen 152.40 yen 356.20 yen
EPS Diluted 122.52 yen
Ann Div 124.00 yen 124.00 yen
-Q2 Div 62.00 yen 62.00 yen
-Q4 Div 62.00 yen 62.00 yen
NOTE - Nippon Shinyaku Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4516.T
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)